Drug Trial Radar · NCT00116649
Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
Last checked: Nov 20, 2026Latest source record: Jul 20, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
551
Actual
Start
Jun 2005
Primary completion
May 2007
Study completion May 2007
Sponsor
- Lead sponsor
- Graceway Pharmaceuticals, LLCIndustry
- Sponsor type
- Industry
- First posted
- Jul 1, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Actinic keratosis (AK) is a skin condition that shows up on skin routinely exposed to the sun, such as the face, scalp, shoulders, chest, back, arms, and hands. The purpose of this study is to evaluate the safety of one, two, or three cycles of imiquimod for the treatment of AK. The AK lesions treated can be in adjacent and nonadjacent areas of the head, torso, and extremities. The total surface area for the AK lesions must be greater than 25 cm2. The secondary objective is to evaluate the effectiveness of treatment with imiquimod in people with large surface areas of AK.
Conditions
- Keratosis
Interventions
imiquimod creamDrug
imiquimod 5% cream applied in doses ranging from one packet (12.5 mg) to 6 packets (75 mg) to either single or multiple body regions for up to 3 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced an Adverse EventTime frame: from first dose up to 18 months
Locations
32 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Encino, California
Site not named
Los Angeles, California
Site not named
Riverside, California
Site not named
San Diego, California
Site not named
Santa Monica, California
Site not named
Denver, Colorado
Site not named
New Britain, Connecticut
Site not named
Coral Gables, Florida
Site not named
Hollywood, Florida
Site not named
Miami, Florida
Site not named
West Palm Beach, Florida
Site not named
Arlington Heights, Illinois
Site not named
Indianapolis, Indiana
Site not named
Metairie, Louisiana
Site not named
Boston, Massachusetts
Site not named
Chaska, Minnesota
Site not named
Henderson, Nevada
Site not named
Henderson, Nevada
Site not named
Reno, Nevada
Site not named
Reno, Nevada
Site not named
New York, New York
Site not named
High Point, North Carolina
Site not named
Raleigh, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Portland, Oregon
Site not named
Flourtown, Pennsylvania
Site not named
Arlington, Texas
Site not named
San Antonio, Texas
Site not named
Woodbridge, Virginia
Site not named
Spokane, Washington
Site not named
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.